Status:
COMPLETED
Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Non-metastatic Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histol...
Eligibility Criteria
Inclusion
- Prostate cancer in the early stage of disease
- Prostate removed and/or radiation therapy to the prostate area
Exclusion
- Previous systemic therapy for prostate cancer
- Previous history of another form of cancer (not prostate) within 5 years of study start.
Key Trial Info
Start Date :
August 1 1995
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
3618 Patients enrolled
Trial Details
Trial ID
NCT00657904
Start Date
August 1 1995
End Date
August 1 2008
Last Update
June 6 2012
Active Locations (85)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Mobile, Alabama, United States
3
Research Site
Scottsdale, Arizona, United States
4
Research Site
Tucson, Arizona, United States